Inventor · disambiguated record
John J. Partridge
Also filed as: PARTRIDGE JOHN · PARTRIDGE JOHN J · PARTRIDGE JOHN JOSEPH · PARTRIDGE JR JOHN J
53 granted patents·19 pending applications·738 citations·filing 1974–2023
99Inventor score
Files withHOFFMANN LA ROCHE21RIGEL PHARMACEUTICALS INC7ENDACEA INC6GLAXO INC5NEUROPRO THERAPEUTICS INC5
Top patents by PatentIndex Score
72 records- 0198US8389557B2Triazole derivatives useful as Axl inhibitorsSINGH RAJINDER·Filed 2010·Granted Mar 5, 2013·73 cites·6 claims
- 0294US8008283B2Methods and compositions for the treatment of neuropsychiatric disordersNEUROTHERAPEUTICS PHARMA INC·Filed 2005·Granted Aug 30, 2011·26 cites·5 claims
- 0394US4804502AVitamin D compoundsHOFFMANN LA ROCHE·Filed 1988·Granted Feb 14, 1989·88 cites·15 claims
- 0493US7884119B2Triazole derivatives useful as Axl inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Feb 8, 2011·23 cites·36 claims
- 0591US7115642B2Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infectionRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Oct 3, 2006·27 cites·17 claims
- 0690US7220745B2Heterocyclic compounds useful to treat HCVRIGEL PHARMACEUTICALS·Filed 2003·Granted May 22, 2007·42 cites·26 claims
- 0789US7326790B2Diphenylisoxazole compounds and hydro isomers thereofRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Feb 5, 2008·23 cites·21 claims
- 0887US9682928B2Bumetanide analogs, compositions and methods of useNEUROPRO THERAPEUTICS INC·Filed 2014·Granted Jun 20, 2017·8 cites·1 claims
- 0987US3933892AAsymmetric synthesis of optically active prostaglandinsHOFFMANN LA ROCHE·Filed 1974·Granted Jan 20, 1976·17 cites·3 claims
- 1086US8901105B2Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamideAFFINIUM PHARM INC·Filed 2013·Granted Dec 2, 2014·8 cites·22 claims
- 1185US3994878ASyntheses of 24R,25- and 24S,25-dihydroxycholesterol and alkanoyl derivatives thereofHOFFMANN LA ROCHE·Filed 1975·Granted Nov 30, 1976·16 cites·45 claims
- 1284US4900828AIntermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidineHOFFMANN LA ROCHE·Filed 1988·Granted Feb 13, 1990·48 cites·21 claims
- 1384US4594340A25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixtureHOFFMANN LA ROCHE·Filed 1984·Granted Jun 10, 1986·23 cites·12 claims
- 1483US6274579B1Pharmaceutically active morpholinolGLAXO WELLCOME INC·Filed 1999·Granted Aug 14, 2001·54 cites·6 claims
- 1583US2024009153A1Bumetanide analogs, compositions and methods of useNEUROPRO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1682US6391875B2Pharmaceutically active morpholinolSMITHKLINE BEECHAM CORP·Filed 2001·Granted May 21, 2002·19 cites·1 claims
- 1781US7332602B2Pyridyl substituted heterocycles useful for treating or preventing HCV infectionRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Feb 19, 2008·3 cites·27 claims
- 1881US7157473B2Pyridyl substituted heterocycles useful for treating or preventing HCV infectionRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Jan 2, 2007·12 cites·57 claims
- 1980US7202252B2A1 adenosine receptor antagonistsENDACEA INC·Filed 2004·Granted Apr 10, 2007·14 cites·17 claims
- 2080US4021423ASyntheses of 24R,25- and 24S,25-dihydroxycholecalciferolHOFFMANN LA ROCHE·Filed 1976·Granted May 3, 1977·12 cites·17 claims
- 2179US10035813B2Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamideDEBIOPHARM INT SA·Filed 2014·Granted Jul 31, 2018·3 cites·27 claims
- 2279US7247639B2A1 adenosine receptor antagonistsENDACEA INC·Filed 2004·Granted Jul 24, 2007·13 cites·4 claims
- 2379US7220761B2Compounds and methods for controlling fungi, bacteria and insectsMYCOSOL INC·Filed 2004·Granted May 22, 2007·11 cites·31 claims
- 2479US4038272AStereospecific syntheses of 24r,25- and 24s,25-dihydroxycholesterol and alkanoyl derivatives thereofHOFFMANN LA ROCHE·Filed 1975·Granted Jul 26, 1977·11 cites·63 claims
- 2579US4028349ASyntheses of 24R,25- and 24S,25-dihydroxycholesterol 24,25-ketals and alkanoyl derivatives thereofHOFFMANN LA ROCHE·Filed 1976·Granted Jun 7, 1977·11 cites·33 claims
- 2678US7423041B2A1 adenosine receptor antagonistsENDACEA INC·Filed 2007·Granted Sep 9, 2008·3 cites·17 claims
- 2776US7820696B2Compounds and methods for controlling fungi, bacteria and insectsMYCOSOL INC·Filed 2007·Granted Oct 26, 2010·2 cites·48 claims
- 2876US5053338AKinetic resolution of pyridazinones using lipaseGLAXO INC·Filed 1990·Granted Oct 1, 1991·16 cites·15 claims
- 2975US6734213B2Pharmaceutically active morpholinolSMITHKLINE BEECHAM CORP·Filed 2002·Granted May 11, 2004·8 cites·3 claims
- 3075US5126452ASynthesis of purine substituted cyclopentene derivativesGLAXO INC·Filed 1990·Granted Jun 30, 1992·16 cites·10 claims
- 3175US4421690AProcess for the preparation of 24,24-difluoro-1α,25-dihydroxy vitamin D3 and intermediates obtained therefromHOFFMANN LA ROCHE·Filed 1982·Granted Dec 20, 1983·11 cites·47 claims
- 3274US4634692ASynthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferolHOFFMANN LA ROCHE·Filed 1984·Granted Jan 6, 1987·10 cites·3 claims
- 3374US4026882ASyntheses of 3,24R,25- and 3,24S,25-trihydroxy-5,7-cholestadiene 24,25-ketals and alkanoyl derivatives thereofHOFFMANN LA ROCHE·Filed 1976·Granted May 31, 1977·8 cites·25 claims
- 3472US2022071935A1Bumetanide analogs, compositions and methods of useNEUROPRO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3571US5233041ASynthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinoneGLAXO GROUP LTD·Filed 1991·Granted Aug 3, 1993·11 cites·13 claims
- 3668US4652405ASynthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferolHOFFMANN LA ROCHE·Filed 1982·Granted Mar 24, 1987·13 cites·47 claims
- 3765US5329008ASynthesis of a 3,4-dihydroxy-1-cyclopentanylpurinoneGLAXO INC·Filed 1993·Granted Jul 12, 1994·7 cites·13 claims
- 3864US2009215754A1Methods and compositions for the treatment of neuropsychiatric and addictive disordersHOCHMAN DARYL W·Filed 2006·Application pending·0 cites
- 3962US2019151263A1Bumetanide analgos, compositions, and methods of useNEUROPRO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4061US7714137B2Pyridyl substituted heterocycles useful for treating or preventing HCV infectionRIGEL PHARMACEUTICALS INC·Filed 2007·Granted May 11, 2010·0 cites·1 claims
- 4161US5438132AMethod for removing osmium from nucleosidesGLAXO GROUP LTD·Filed 1993·Granted Aug 1, 1995·6 cites·2 claims
- 4260US2008293705A1A1 adenosine receptor antagonistsENDACEA INC·Filed 2008·Application pending·0 cites
- 4358US2017246131A1Bumetanide analogs, compositions, and methods of useNEUROPRO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4458US2006189612A1Pharmaceutically active morpholinolSMITHKLINE BEECHAM CORP·Filed 2006·Application pending·0 cites
- 4556US4137244AAsymmetric synthesis of optically active prostaglandinsHOFFMANN LA ROCHE·Filed 1977·Granted Jan 30, 1979·2 cites·1 claims
- 4656US4127736A2-Hydroxyethyl-3-cyclopenten-1-ols and derivatives thereofHOFFMANN LA ROCHE·Filed 1977·Granted Nov 28, 1978·2 cites·2 claims
- 4755US7902360B2A1 adenosine receptor antagonistsWILSON CONSTANCE N·Filed 2007·Granted Mar 8, 2011·0 cites·2 claims
- 4855US7547444B1Methods for controlling fungi and bacteriaMYCOSOL INC·Filed 2004·Granted Jun 16, 2009·0 cites·14 claims
- 4954US5241069ACarbonate intermediates for the synthesis of purine substituted cyclopentene derivativesGLAXO INC·Filed 1991·Granted Aug 31, 1993·4 cites·2 claims
- 5054US4617297AMethod of treating disease states by the administration of 1α,25,26-trihydroxycholecalciferolHOFFMANN LA ROCHE·Filed 1984·Granted Oct 14, 1986·13 cites·12 claims
Showing the top 50 of 72 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John J. Partridge files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →